From Seed to Sale: What VC’s Want in Biotech Startups
Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, metabolic/diabetes). He explains how AI is …
Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, metabolic/diabetes). He explains how AI is …
Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, metabolic/diabetes). He explains how AI is …
The full story continues on The Street.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.